Category: 364-12-5

On October 12, 2017, Patil, Rakesh Ishwar; Gunjal, Amol Pandurang; Verma, Jeevan; Kumar, Puneet; Rai, Santosh Kumar; Rai, Himanshu; Kumar, Anil published a patent.Synthetic Route of 364-12-5 The title of the patent was Preparation of heterocyclic compounds as GPR119 agonist for treatment of metabolic disorders. And the patent contained the following:

The invention relates to novel compounds of formula I as GPR119 agonist, compositions containing such compounds and method of their preparation which are useful for the prevention or treatment of metabolic disorders including diabetes mellitus type I and type II. I [wherein X1, X2, X3, X4, and X5 independently = N, O, S, or CH; R1 and R2 independently = H, O, C1-6alkyl, amino, etc.; A = tetrazol-1-ylphenyl-, 4-dimethylaminocarbonyl-Ph, 1-benzyl-piperazin-4-yl, etc.; B = morpholin-4-ylcarbonyl-Ph, -CH2OH, 4-cyano-Ph, etc.; n = 0, 1, 2, or 3] or a pharmaceutically acceptable salt, hydrate, or stereoisomer thereof, are claimed and exemplified. Example compound II was prepared from the oxidation of the corresponding sulfanyl intermediate in 37.62% yield. Exemplified I were evaluated for antidiabetic activity using an oral glucose tolerance test in mice and Sprague-Dawley rats from which II demonstrated dose-dependent reduction of glucose at 3mpk and 10mpk. The experimental process involved the reaction of 5-Bromo-2-iodobenzotrifluoride(cas: 364-12-5).Synthetic Route of 364-12-5

The Article related to heterocyclic compound preparation gpr119 metabolic disease diabetes, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Synthetic Route of 364-12-5

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On October 15, 2015, Loso, Michael R.; Gustafson, Gary D.; Kubota, Asako; Yap, Maurice C.; Buchan, Zachary A.; Steward, Kimberly M.; Sullenberger, Michael T.; Hoekstra, William J.; Yates, Christopher M. published a patent.COA of Formula: C7H3BrF3I The title of the patent was Preparation of metalloenzyme inhibitor compounds as fungicides for pharmaceutical and agricultural use. And the patent contained the following:

The invention describes compounds of formula I having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes as well the use of I to protect and/or cure plants against damage caused by agriculturally relevant fungi. I [wherein Z is (un)substituted pyrimidinyl, thiazolyl, oxazolyl, etc.; R1 is alkyl, haloalkyl, (hetero)aryl, etc.; R2 is aryl or heteroaryl; R3 is H, alkyl, (hetero)aryl, etc.; R4, R5, R6, and R7 are independently H, alkyl, alkoxy, etc.] are claimed and exemplified. Coupling of 1-(4-bromophenyl)-2,2-dimethyl-1-(pyrimidin-5-yl)propan-1-ol with (4-(trifluoromethoxy)phenyl)boronic acid provided II in 93% yield. Candidate compounds of I were evaluated for fungicidal activity against Leaf Blotch of Wheat (Mycosphaerella graminicola; Anamorph; Septoria tritica; Bayer Code SEPTTR)(data given). The experimental process involved the reaction of 5-Bromo-2-iodobenzotrifluoride(cas: 364-12-5).COA of Formula: C7H3BrF3I

The Article related to metalloenzyme inhibitor preparation pharmaceutical agricultural fungicide, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.COA of Formula: C7H3BrF3I

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

Kaneko, Yuzuru; Hayashi, Mimi; Agata, Hideharu; Ichinohe, Tatsuya; Kaneko, Yuzuru published an article in 2001, the title of the article was Propofol does not change the platelet retention rate.HPLC of Formula: 364-12-5 And the article contains the following content:

An acceleration of platelet aggregations during and after surgery increases the risks of perioperative myocardial or cerebral infarction. It has been reported that isoflurane and sevoflurane depress platelet aggregation, but there are no convincing reports about the effects of propofol. We therefore investigated the effect of propofol on platelet aggregation by determining the platelet retention rate (PRR). Twenty-six consenting oral surgical patients classified in ASA phys. status I were randomly assigned to one of two groups (GOS group: n=13; GOP group: n=13). The patients in the GOS group were induced with thiopental sodium, nasotracheally intubated with vecuronium bromide, and maintained with 60% nitrous oxide and 1.5% sevoflurane in oxygen. The patients in the GOP group were induced with propofol, nasotracheally incubated with vecuronium bromide, and maintained with 60% nitrous oxide and 10 mg/kg/h propofol in oxygen. The PRR was determined by the collagen bead column method. Venous blood was collected three times in each group for the determination of PRR. The first PRR was measured before the induction of anesthesia, the second PRR, after the induction of anesthesia, and the third PRR, 5 min after submucosal injection of 5 mL of 1% lidocaine solution containing epinephrine (1:100,000). Data were analyzed using one-way ANOVA for repeated measurements followed by Student-Newman-Keuls test for intragroup comparisons and Student’s t-test for unpaired samples for intergroup comparisons p values less than 0.05 indicated statistical significance. The PRR in the GOS group decreased after induction (36.4卤12.5%) and increased after local anesthesia (52.3卤17.0%) when compared with that before induction (45.2卤14.2%). The PRR in GOP group did not decrease after induction (43.0卤13.0%), but it also increased after local anesthesia (56.0卤12.9%) when compared with that before induction (42.1卤13.1%). These data were all within normal ranges. The PRR changes after induction were -8.7卤9.1% in GOS group and 0.8卤6.2% in GOP group, resp. (p<0.05 between two groups). In contrast, the PRR increased in both groups after local anesthesia (GOS group = 15.8卤9.6%; GOP group = 13.8卤12.8%). In conclusion, propofol has no or minimal effect on platelet aggregation. The inhibitory effects of sevoflurane and propofol on epinephrine-induced platelet aggregation may be similar. The experimental process involved the reaction of 5-Bromo-2-iodobenzotrifluoride(cas: 364-12-5).HPLC of Formula: 364-12-5

The Article related to propofol anesthetic platelet aggregation, Pharmacology: Effects Of Nervous System- and Behavior-Affecting Drugs and Neuromuscular Agents and other aspects.HPLC of Formula: 364-12-5

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On January 2, 2015, Shi, Guangfa; Shao, Changdong; Pan, Shulei; Yu, Jingxun; Zhang, Yanghui published an article.Computed Properties of 364-12-5 The title of the article was Silver-Catalyzed C-H Trifluoromethylation of Arenes Using Trifluoroacetic Acid as the Trifluoromethylating Reagent. And the article contained the following:

Direct trifluoromethylation of arenes using TFA as the trifluoromethylating reagent was achieved with Ag as the catalyst. This reaction not only provides a new protocol for aryl C-H trifluoromethylation, but the generation of CF3路 from TFA may prove useful in other contexts and could potentially be extended to other trifluoromethylation reactions. The experimental process involved the reaction of 5-Bromo-2-iodobenzotrifluoride(cas: 364-12-5).Computed Properties of 364-12-5

The Article related to silver catalyst trifluoromethylation arene trifluoroacetic acid, carbon hydrogen bond activation green chem, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Halides and Halonium Compounds and other aspects.Computed Properties of 364-12-5

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com

On July 26, 2021, Dorian, Andreas; Landgreen, Emily J.; Petras, Hayley R.; Shepherd, James J.; Williams, Florence J. published an article.Recommanded Product: 364-12-5 The title of the article was Iron-Catalyzed Halogen Exchange of Trifluoromethyl Arenes. And the article contained the following:

The facile production of ArCF2X and ArCX3 from ArCF3 using catalytic iron(III)halides is reported, which constitutes the first iron-catalyzed halogen exchange for non-aromatic C-F bonds. Theor. calculations suggest direct activation of C-F bonds by iron coordination. ArCX3 and ArCF2X products of the reaction are synthetically valuable due to their diversification potential. In particular, chloro- and bromodifluoromethyl arenes (ArCF2Cl, ArCF2Br resp.) provide access to a myriad of difluoromethyl arene derivatives (ArCF2R). To optimize for mono-halogen exchange, a statistical method called Design of Experiments was used. Optimized parameters were successfully applied to electron rich and electron deficient aromatic substrates, and to the late stage diversification of flufenoxuron, a com. insecticide. These methods are highly practical, being run at convenient temperatures and using inexpensive common reagents. The experimental process involved the reaction of 5-Bromo-2-iodobenzotrifluoride(cas: 364-12-5).Recommanded Product: 364-12-5

The Article related to ferric boron halide catalyzed halogen exchange trifluoromethyl arene, c鈭抐 activation, defluorination, halogen exchange, iron catalysis, late-stage modification, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Halides and Halonium Compounds and other aspects.Recommanded Product: 364-12-5

Referemce:
Iodide – Wikipedia,
Iodide – an overview | ScienceDirect Topics – ScienceDirect.com